Dynamics of a Nosocomial Outbreak of Multidrug-Resistant Pseudomonas aeruginosa Producing the PER-1 Extended-Spectrum β-Lactamase

ABSTRACT From November 1998 to August 1999, a large outbreak occurred in the general intensive care unit of the Ospedale di Circolo in Varese (Italy), caused by Pseudomonas aeruginosa producing the PER-1 extended-spectrum β-lactamase. A total of 108 clinical isolates of P. aeruginosa resistant to broad-spectrum cephalosporins were recovered from 18 patients. Epidemic isolates were characterized by synergy between clavulanic acid and ceftazidime, cefepime, and aztreonam. Isoelectric focusing of crude bacterial extracts detected two nitrocefin-positive bands with pI values of 8.0 and 5.3. PCR amplification and characterization of the amplicons by restriction analysis and direct sequencing indicated that the epidemic isolates carried a blaPER-1 determinant. The outbreak was of clonal origin as shown by pulsed-field gel electrophoresis analysis. This technique also indicated that the epidemic strain was not related to three other PER-1-positive isolates obtained at the same hospital in 1997. Typing by enterobacterial repetitive intergenic consensus-PCR showed that minor genetic variations occurred during the outbreak. The epidemic strain was characterized by a multiple-drug-resistance phenotype that remained unchanged over the outbreak, including extended-spectrum cephalosporins, monobactams, aminoglycosides, and fluoroquinolones. Isolation of infected patients and appropriate carbapenem therapy were successful in ending the outbreak. Our report indicates that theblaPER-1 resistance determinant may become an emerging therapeutic problem in Europe.

[1]  S. Lory,et al.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen , 2000, Nature.

[2]  M. Vaneechoutte,et al.  PER-1 β-lactamase-producing Pseudomonas aeruginosa in an intensive care unit , 2000 .

[3]  L. Bush,et al.  Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations. , 2000, Infectious disease clinics of North America.

[4]  C. Gentry,et al.  Increasing antimicrobial resistance in gram-negative bacilli isolated from patients in intensive care units. , 2000, American journal of infection control.

[5]  G. Cornaglia,et al.  Carbapenem-resistant Pseudomonas aeruginosa with acquired bla(vim) metallo-beta-lactamase determinants, Italy. , 2000, Emerging infectious diseases.

[6]  J. Verhoef,et al.  Antimicrobial Resistance in European Isolates of Pseudomonas aeruginosa , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[7]  N. Woodford,et al.  Outbreak of Infections Caused by Pseudomonas aeruginosa Producing VIM-1 Carbapenemase in Greece , 2000, Journal of Clinical Microbiology.

[8]  D. Sirot,et al.  Production of a TEM-24 Plasmid-Mediated Extended-Spectrum β-Lactamase by a Clinical Isolate ofPseudomonas aeruginosa , 2000, Antimicrobial Agents and Chemotherapy.

[9]  P. Nordmann,et al.  Extended-spectrum β-lactamase TEM-4 in Pseudomonas aeruginosa. , 1999, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  H. Sader,et al.  Nosocomial Infections Caused by Multiresistant Pseudomonas aeruginosa , 1999, Infection Control & Hospital Epidemiology.

[11]  D. Michael Olive,et al.  Principles and Applications of Methods for DNA-Based Typing of Microbial Organisms , 1999, Journal of Clinical Microbiology.

[12]  E. Bouza,et al.  Pseudomonas aeruginosa: a Survey of Resistance in 136 Hospitals in Spain , 1999, Antimicrobial Agents and Chemotherapy.

[13]  T. Köhler,et al.  Patterns and modes of β-lactam resistance in Pseudomonas aeruginosa , 1999 .

[14]  M. Gründling,et al.  A large outbreak of multiresistant Pseudomonas aeruginosa strains in north-eastern Germany. , 1999, The Journal of antimicrobial chemotherapy.

[15]  H. Domdey,et al.  Safety and Immunogenicity of a Pseudomonas aeruginosa Hybrid Outer Membrane Protein F-I Vaccine in Human Volunteers , 1999, Infection and Immunity.

[16]  L E Nilsson,et al.  Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. , 1999, JAMA.

[17]  A. D. Russell,et al.  Antiseptics and Disinfectants: Activity, Action, and Resistance , 1999, Clinical Microbiology Reviews.

[18]  P. Nordmann,et al.  Extended-spectrum beta-lactamases in Pseudomonas aeruginosa. , 1998, The Journal of antimicrobial chemotherapy.

[19]  R. Hancock Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  H. Vahaboğlu,et al.  Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp. , 1998, The Journal of antimicrobial chemotherapy.

[21]  W. Traub,et al.  Surveillance of Pseudomonas aeruginosa in Intensive Care Units: Clusters of Nosocomial Cross-Infection and Encounter of a Multiple-Antibiotic Resistant Strain , 1998, Chemotherapy.

[22]  G. Bonfiglio,et al.  Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey. , 1998, The Journal of antimicrobial chemotherapy.

[23]  H. Leblebicioglu,et al.  Widespread Detection of PER-1-Type Extended-Spectrum β-Lactamases among NosocomialAcinetobacter and Pseudomonas aeruginosaIsolates in Turkey: a Nationwide Multicenter Study , 1998, Antimicrobial Agents and Chemotherapy.

[24]  H. Leblebicioglu,et al.  Widespread detection of PER-1-type extended-spectrum beta-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study , 1997, Antimicrobial agents and chemotherapy.

[25]  M. Rué,et al.  Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  D. Livermore beta-Lactamases in laboratory and clinical resistance , 1995, Clinical microbiology reviews.

[27]  D. Livermore,et al.  Resistance to extended-spectrum cephalosporins, caused by PER-1 beta-lactamase, in Salmonella typhimurium from Istanbul, Turkey. , 1995, Journal of medical microbiology.

[28]  D H Persing,et al.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing , 1995, Journal of clinical microbiology.

[29]  J. Vincent,et al.  The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. , 1995, JAMA.

[30]  G. Jacoby,et al.  A functional classification scheme for beta-lactamases and its correlation with molecular structure , 1995, Antimicrobial agents and chemotherapy.

[31]  D. Livermore,et al.  Transferable production of PER-1 β-lactamase in Pseudomonas aeruginosa , 1995 .

[32]  P. Nordmann,et al.  Sequence analysis of PER-1 extended-spectrum beta-lactamase from Pseudomonas aeruginosa and comparison with class A beta-lactamases , 1994, Antimicrobial Agents and Chemotherapy.

[33]  P. Nordmann,et al.  Characterization of a novel extended-spectrum beta-lactamase from Pseudomonas aeruginosa , 1993, Antimicrobial Agents and Chemotherapy.

[34]  J. Lupski,et al.  Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. , 1991, Nucleic acids research.

[35]  J R Roth,et al.  Ability of a bacterial chromosome segment to invert is dictated by included material rather than flanking sequence. , 1991, Genetics.

[36]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[37]  S. Lory,et al.  Complete genome sequence of Pseudomonas aeruginosa PAO 1 , an opportunistic pathogen , 2000 .

[38]  G. Rossolini,et al.  PER-1 extended-spectrum beta-lactamase production in an Alcaligenes faecalis clinical isolate resistant to expanded-spectrum cephalosporins and monobactams from a hospital in Northern Italy. , 2000, Microbial drug resistance.

[39]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[40]  D. Livermore,et al.  Transferable production of PER-1 beta-lactamase in Pseudomonas aeruginosa. , 1995, The Journal of antimicrobial chemotherapy.

[41]  J. Waitz Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .

[42]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .